Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Apr;71(4):873–876. doi: 10.1038/bjc.1995.168

Measurement of response to treatment in colorectal liver metastases.

M J Dworkin 1, D Burke 1, S Earlam 1, C Fordy 1, T G Allen-Mersh 1
PMCID: PMC2033728  PMID: 7710957

Abstract

Assessment of tumour response to chemotherapy is important when assessing efficacy of treatment and comparing differing therapeutic regimens. Percentage hepatic replacement (PHR) is commonly used to assess response to treatment of colorectal hepatic metastases. PHR is dependent not only on tumour volume, but also on hepatic parenchymal volume. The effect of tumour growth on hepatic parenchymal volume is unclear but is of importance owing to its effect on PHR. We assessed tumour and hepatic parenchymal weights in an animal tumour model using dissection, and tumour and hepatic parenchymal volumes in patients with colorectal hepatic metastases using CT scanning, in order to establish how hepatic parenchyma varied with change in metastasis size. There was no significant correlation between tumour and liver parenchyma in either the animal model (r = -0.03, P > 0.05) or the patient study (r = 0.3, P < 0.05). This suggests that hepatic parenchymal volume was preserved in the presence of increasing tumour volume. In a further study of computerised tomographic (CT) scans before and after treatment in patients whose tumours either responded to chemotherapy or continued to grow, change in PHR (median proportion of PHR change = 0.40) significantly (P = 0.04) underestimated the change in tumour volume (median proportion of tumour volume change = 0.56), particularly at higher (> 400 ml) volumes. There was good correlation between change in tumour volume and WHO criteria in assigning patients to tumour growth, stable disease or tumour response categories. This study suggests that, in clinical trials comparing colorectal liver metastasis treatments, metastasis volume and not PHR should be used to assess extent of disease and the effect of treatment.

Full text

PDF
873

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen-Mersh T. G., Earlam S., Fordy C., Abrams K., Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet. 1994 Nov 5;344(8932):1255–1260. doi: 10.1016/s0140-6736(94)90750-1. [DOI] [PubMed] [Google Scholar]
  2. Allen-Mersh T. G., Kemeny N., Niedzwiecki D., Shurgot B., Daly J. M. Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut. 1987 Dec;28(12):1625–1629. doi: 10.1136/gut.28.12.1625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Breiman R. S., Beck J. W., Korobkin M., Glenny R., Akwari O. E., Heaston D. K., Moore A. V., Ram P. C. Volume determinations using computed tomography. AJR Am J Roentgenol. 1982 Feb;138(2):329–333. doi: 10.2214/ajr.138.2.329. [DOI] [PubMed] [Google Scholar]
  4. Dworkin M. J., Allen-Mersh T. G. Regional infusion chemotherapy for colorectal hepatic metastases--where is it going? Cancer Treat Rev. 1991 Dec;18(4):213–224. doi: 10.1016/0305-7372(91)90013-p. [DOI] [PubMed] [Google Scholar]
  5. Eccles S. A., Box G., Court W., Collins M. K., Dean C. J. Monoclonal antibodies for the treatment of metastases. Evaluation of strategies using a syngeneic rat model. Cell Biophys. 1993 Jan-Jun;22(1-3):165–187. doi: 10.1007/BF03033873. [DOI] [PubMed] [Google Scholar]
  6. Erlichman C., Fine S., Wong A., Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol. 1988 Mar;6(3):469–475. doi: 10.1200/JCO.1988.6.3.469. [DOI] [PubMed] [Google Scholar]
  7. Heymsfield S. B., Fulenwider T., Nordlinger B., Barlow R., Sones P., Kutner M. Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography. Ann Intern Med. 1979 Feb;90(2):185–187. doi: 10.7326/0003-4819-90-2-185. [DOI] [PubMed] [Google Scholar]
  8. Hunt T. M., Flowerdew A. D., Taylor I., Ackery D. M., Blaquiere R. M., Dewbury K. A comparison of methods to measure the percentage hepatic replacement with colorectal metastases. Ann R Coll Surg Engl. 1989 Jan;71(1):11–13. [PMC free article] [PubMed] [Google Scholar]
  9. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  10. Purkiss S. F., Williams N. S. Growth rate and percentage hepatic replacement of colorectal liver metastases. Br J Surg. 1993 Aug;80(8):1036–1038. doi: 10.1002/bjs.1800800838. [DOI] [PubMed] [Google Scholar]
  11. Rougier P., Laplanche A., Huguier M., Hay J. M., Ollivier J. M., Escat J., Salmon R., Julien M., Roullet Audy J. C., Gallot D. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol. 1992 Jul;10(7):1112–1118. doi: 10.1200/JCO.1992.10.7.1112. [DOI] [PubMed] [Google Scholar]
  12. Taves D. R. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther. 1974 May;15(5):443–453. doi: 10.1002/cpt1974155443. [DOI] [PubMed] [Google Scholar]
  13. Ward B. A., Miller D. L., Frank J. A., Dwyer A. J., Simmons J. T., Chang R., Shawker T. H., Choyke P., Chang A. E. Prospective evaluation of hepatic imaging studies in the detection of colorectal metastases: correlation with surgical findings. Surgery. 1989 Feb;105(2 Pt 1):180–187. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES